418 related articles for article (PubMed ID: 25322075)
21. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
23. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
24. Tiotropium versus salmeterol in COPD.
Schembri S
N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714655
[No Abstract] [Full Text] [Related]
25. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis.
Tian JW; Chen JW; Chen R; Chen X
Respir Care; 2014 May; 59(5):654-66. PubMed ID: 24170916
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review.
Rodrigo GJ; Neffen H
Pediatr Allergy Immunol; 2017 Sep; 28(6):573-578. PubMed ID: 28692145
[TBL] [Abstract][Full Text] [Related]
27. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.
Kerstjens HA; Moroni-Zentgraf P; Tashkin DP; Dahl R; Paggiaro P; Vandewalker M; Schmidt H; Engel M; Bateman ED
Respir Med; 2016 Aug; 117():198-206. PubMed ID: 27492532
[TBL] [Abstract][Full Text] [Related]
28. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
29. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.
Hamelmann E; Bernstein JA; Vandewalker M; Moroni-Zentgraf P; Verri D; Unseld A; Engel M; Boner AL
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 27811070
[TBL] [Abstract][Full Text] [Related]
30. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma.
Fardon T; Haggart K; Lee DK; Lipworth BJ
Respir Med; 2007 Jun; 101(6):1218-28. PubMed ID: 17178217
[TBL] [Abstract][Full Text] [Related]
31. A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.
Rodrigo GJ; Neffen H
Chest; 2015 Aug; 148(2):397-407. PubMed ID: 25798635
[TBL] [Abstract][Full Text] [Related]
32. Tiotropium bromide as add-on therapy to inhaled corticosteroids for treating asthma.
Matsuse H; Yamagishi T; Kodaka N; Miura A; Kurose Y; Nakano C; Oshio T
Expert Opin Pharmacother; 2015 Jun; 16(9):1403-9. PubMed ID: 26001185
[TBL] [Abstract][Full Text] [Related]
33. Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.
Casale TB; Bateman ED; Vandewalker M; Virchow JC; Schmidt H; Engel M; Moroni-Zentgraf P; Kerstjens HAM
J Allergy Clin Immunol Pract; 2018; 6(3):923-935.e9. PubMed ID: 29174062
[TBL] [Abstract][Full Text] [Related]
34. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review.
Joos S; Miksch A; Szecsenyi J; Wieseler B; Grouven U; Kaiser T; Schneider A
Thorax; 2008 May; 63(5):453-62. PubMed ID: 18443162
[TBL] [Abstract][Full Text] [Related]
35. Tiotropium for the treatment of asthma in adolescents.
Hamelmann E; Vogelberg C; Szefler SJ
Expert Opin Pharmacother; 2017 Feb; 18(3):305-312. PubMed ID: 28110558
[TBL] [Abstract][Full Text] [Related]
36. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids.
Chan J; Hui RL; Spence MM
J Manag Care Pharm; 2007; 13(1):21-7. PubMed ID: 17269833
[TBL] [Abstract][Full Text] [Related]
37. Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics.
Casale TB; Aalbers R; Bleecker ER; Meltzer EO; Zaremba-Pechmann L; de la Hoz A; Kerstjens HAM
Respir Med; 2019; 158():97-109. PubMed ID: 31654891
[TBL] [Abstract][Full Text] [Related]
38. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review.
Rodrigo GJ; Moral VP; Marcos LG; Castro-Rodriguez JA
Pulm Pharmacol Ther; 2009 Feb; 22(1):9-19. PubMed ID: 19026757
[TBL] [Abstract][Full Text] [Related]
39. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.
Cramer JA; Bradley-Kennedy C; Scalera A
Can Respir J; 2007; 14(1):25-9. PubMed ID: 17315055
[TBL] [Abstract][Full Text] [Related]
40. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
